| dc.contributor.author | Day, S | |
| dc.contributor.author | Graham, SM | |
| dc.contributor.author | Masese, LN | |
| dc.contributor.author | Richardson, BA | |
| dc.contributor.author | Kiarie, JN | |
| dc.contributor.author | Jaoko, W | |
| dc.contributor.author | Mandaliya, K | |
| dc.contributor.author | chohan, V | |
| dc.contributor.author | Overbaugh, J | |
| dc.contributor.author | McClelland, Scott R. | |
| dc.date.accessioned | 2014-05-09T08:35:19Z | |
| dc.date.available | 2014-05-09T08:35:19Z | |
| dc.date.issued | 2014-05 | |
| dc.identifier.citation | J Acquir Immune Defic Syndr. 2014 May 4. [Epub ahead of print] | en_US |
| dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pubmed/24798764 | |
| dc.identifier.uri | http://hdl.handle.net/11295/66399 | |
| dc.description.abstract | Depot medroxyprogesterone acetate (DMPA) use among HIV-1 infected women may increase transmission by increasing plasma and genital HIV-1 RNA shedding. We investigated associations between DMPA use and HIV-1 RNA in plasma and cervical secretions. 102 women initiated ART, contributing 925 follow-up visits over a median of 34 months. Compared to visits with no hormonal contraception exposure, DMPA exposure did not increase detection of plasma (adjusted odds ratio (AOR) 0.81, 95% CI 0.47-1.39) or cervical HIV-1 RNA (AOR 1.41, 95% CI 0.54-3.67). Our results suggest that DMPA is unlikely to increase infectivity in HIV-positive women who are adherent to effective ART. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | University of Nairobi | en_US |
| dc.title | A Prospective Cohort Study of the Effect of Depot Medroxyprogesterone Acetate on Detection of Plasma and Cervical HIV-1 in Women Initiating and Continuing Antiretroviral Therapy | en_US |
| dc.type | Article | en_US |
